GenoMed's Treatment for West Nile Virus Aired in Time for Most St. Louis Cases; Inaction by Media and Public Health Authorities Hampers Efforts in Rest of U.S.
CONTACT: GenoMed Inc.
David W. Moskowitz, MD, MA, FACP
(314) 983-9933 dwmoskowitz@genomedics.com
FOR IMMEDIATE RELEASE
ST. LOUIS, MO. – July 29, 2004 – GenoMed, Inc. (Pink Sheets: GMED), a Next Generation DM™ (Disease Management) company that uses its expertise in genomics to improve clinical outcomes, announced today that its patent-pending approach to West Nile virus encephalitis is becoming better known to the public just in time for the peak in West Nile virus cases that traditionally occurs in August.
Fox 2 KTVI in St. Louis aired a news segment at 9 pm two nights ago about GenoMed's unusual and highly successful approach. Mention of GenoMed's trial can be found at the KTVI website, www.fox2ktvi.com, under "Website Links."
GenoMed's is the only treatment for West Nile virus using already existing, extremely safe, FDA-approved medications. It is the only treatment published in the medical literature which is 100% successful so far for patients with a normal immune system. It is the only treatment which could be safely used for the entire population immediately. Unfortunately, GenoMed's treatment has not yet been publicized in the Western U.S., especially Arizona, where most of the cases of West Nile virus have occurred so far this summer.
For more information, click on the "West Nile trial" link at genomedics.com.
About GenoMed
GenoMed is leading the clinical revolution which medical genomics has already made possible. GenoMed is currently marketing its protocol for preventing kidney failure due to high blood pressure and diabetes, and delaying emphysema. This summer, GenoMed's goal was to eliminate the threat of West Nile virus from the general population on the 50th anniversary of the famous 1954 polio field trials which ended the threat of polio in the U.S. Because of inaction by most of the media and all of the public health authorities to date, GenoMed urges people to take it upon themselves to tell their family members and friends about our trial. The person you tell could be the life you save.
In financial news, GenoMed and Pierpoint Investissements SA have decided not to raise any private funds for the company until GenoMed's share price again reaches 20 cents, so as to avoid dilution to existing investors.
. |
